Effects of topical administration of levocabastine on psychomotor and cognitive function.
The possible central nervous system effects of topical administration of levocabastine, a new H1-antagonist, were investigated in a double-blind, placebo-controlled, crossover study using a battery of objective and subjective tests. These were carried out in 12 volunteers up to five hours postapplication. Neither the recommended (0.5 mg/mL) nor the four times higher (2.0 mg/mL) concentration level was found to be distinguishable from placebo, while the verum (triprolidine 10 mg) was significantly worse, on both objective and subjective measures.
Human Psychopharmacology Research Unit, Robens Institute, University of Surrey, England.
N
N
Rombaut
J Z
JZ
Bhatti
S
S
Curran
I
I
Hindmarch
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D003071:Cognition / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology*
D006634:Histamine H1 Antagonists; D010880:Piperidines; C047340:levocabastine